What podcasts say about Albert Bourla

Every statement, with the speaker, the exact quote and the moment it was said.

What Albert Bourla has said on podcasts

11 statements · 8 positive · 2 negative · 1 neutral

on Pfizer obesity-treatment programPositiveJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer will start ten Phase 3 obesity studies in 2026.
“We are going to start 10 phase three studies this year.”
Listen at 25:49
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Pfizer ultra-long-acting GLP-1PositiveJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer expects its ultra-long-acting GLP-1 to be highly differentiated.
“we hope to demonstrate how highly differentiated the ultra-long-acting GLP-1 it is compared to the long-acting GLP-1s of the others.”
Listen at 26:09
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Pfizer obesity-treatment programPositiveJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer expects to play a significant role in obesity treatment.
“we will be able to play a very significant role.”
Listen at 27:01
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Pfizer dividendPositiveJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer’s dividend should remain reliable despite upcoming patent losses.
“you should not worry about the dividend.”
Listen at 27:21
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Nurtec menstrual-migraine studyNeutralJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer expects menstrual-migraine study results by late 2026 or 2027.
“we expect to read out probably next year, maybe end of this year, but probably next year, on menstrual migraines.”
Listen at 29:38
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Pfizer MFN pricing agreementPositiveJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer’s MFN agreement will reduce the US-Europe drug-price gap.
“We couldn't have prices in the US for products that are two or three times higher than in Europe. So that is changing and will change.”
Listen at 31:00
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on HHS vaccine policiesNegativeJan 13, 2026· Mad Money w/ Jim Cramer
Unscientific HHS actions on vaccines will cost lives.
“Everything they do, it is not science-based, will cost lives.”
Listen at 31:47
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Pfizer revenueNegativeJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer revenue will stagnate or slightly decline through 2028.
“we will have stagnation and probably small decline all the way to 28.”
Listen at 32:40
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Pfizer revenue growthPositiveJan 13, 2026· Mad Money w/ Jim Cramer
“the CAGR of that period will be industry leading.”
Listen at 32:49
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Pfizer acquisitions and new launchesPositiveJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer expects $10 billion from acquisitions and launches in 2026, with double-digit growth.
“This year, probably will make $10 billion from new acquisitions and new launches with double-digit growth.”
Listen at 34:02
Open the episode · Mad Money w/ Jim Cramer 1/12/26
on Pfizer revenue growthPositiveJan 13, 2026· Mad Money w/ Jim Cramer
Pfizer expects double-digit growth in 2026.
“next year, so this year, 26, we will maintain the double-digit growth.”
Listen at 34:11
Open the episode · Mad Money w/ Jim Cramer 1/12/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.